{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:50:39Z","timestamp":1786114239705,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020450","name":"Suzhou University","doi-asserted-by":"publisher","award":["ZDXM2025011"],"award-info":[{"award-number":["ZDXM2025011"]}],"id":[{"id":"10.13039\/501100020450","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020450","name":"Suzhou University","doi-asserted-by":"publisher","award":["SYW2024007"],"award-info":[{"award-number":["SYW2024007"]}],"id":[{"id":"10.13039\/501100020450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.acra.2026.06.063","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:27:27Z","timestamp":1784838447000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Habitat-Based Radiomic Quantification of Intratumoral Heterogeneity on Digital Breast Tomosynthesis for Predicting HER2 Status in Invasive Breast Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7478-2338","authenticated-orcid":false,"given":"Yifan","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1504-4773","authenticated-orcid":false,"given":"Shuangqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acra.2026.06.063_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives","volume":"9","author":"Arteaga","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.acra.2026.06.063_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.acra.2026.06.063_bib3","first-page":"617","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"17","key":"10.1016\/j.acra.2026.06.063_bib4","first-page":"1887","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low\u2013expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"8","key":"10.1016\/j.acra.2026.06.063_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.acra.2026.06.063_bib6","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.acra.2026.06.063_bib7","first-page":"3867","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"10","key":"10.1016\/j.acra.2026.06.063_bib8","first-page":"1352","article-title":"Radiomics signatures based on multiparametric MRI for the preoperative prediction of the HER2 status of patients with breast cancer","volume":"28","author":"Zhou","year":"2021","journal-title":"Acad\u00a0Radiol"},{"issue":"05","key":"10.1016\/j.acra.2026.06.063_bib9","first-page":"549","article-title":"Assessment of HER2 status in breast cancer based on intratumoral and peritumoral radiomics","volume":"30","author":"ZHANG","year":"2024","journal-title":"Chin\u00a0Comput\u00a0Med\u00a0Imaging"},{"issue":"1","key":"10.1016\/j.acra.2026.06.063_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12885-025-13549-7","article-title":"Revolutionizing HER-2 assessment: multidimensional radiomics in breast cancer diagnosis","volume":"25","author":"Xie","year":"2025","journal-title":"BMC cancer"},{"issue":"07","key":"10.1016\/j.acra.2026.06.063_bib11","first-page":"1203","article-title":"The predictive value of deep learning models based on FFDM and DBT features for HER2 expression status in invasive breast cancer","volume":"44","author":"GONG","year":"2025","journal-title":"J\u00a0Clin\u00a0Radiol"},{"issue":"1","key":"10.1016\/j.acra.2026.06.063_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13058-024-01921-7","article-title":"Quantification of intratumoral heterogeneity using habitat-based MRI radiomics to identify HER2-positive,-low and-zero breast cancers: a multicenter study","volume":"26","author":"Chen","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.acra.2026.06.063_bib13","first-page":"1613","article-title":"Whole tumour-and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: a double-centre pilot study","volume":"131","author":"Wang","year":"2024","journal-title":"Br\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.acra.2026.06.063_bib14","article-title":"MRI-based habitat analysis for Intratumoral heterogeneity quantification combined with deep learning for HER2 status prediction in breast cancer","volume":"122","author":"Li","year":"2025","journal-title":"Magn\u00a0Reson\u00a0Imaging"},{"issue":"1","key":"10.1016\/j.acra.2026.06.063_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1148\/radiol.12120674","article-title":"Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial","volume":"266","author":"Rafferty","year":"2013","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.acra.2026.06.063_bib16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1148\/rg.2021210017","article-title":"Upright tomosynthesis-guided breast biopsy: tips, tricks, and troubleshooting","volume":"41","author":"Vijapura","year":"2021","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.acra.2026.06.063_bib17","first-page":"75","article-title":"CheckList for EvaluAtion of Radiomics research (CLEAR): a step-by-step reporting guideline for authors and reviewers endorsed by ESR and EuSoMII[J]","volume":"14","author":"Kocak","year":"2023","journal-title":"Insights\u00a0Imaging"},{"issue":"3","key":"10.1016\/j.acra.2026.06.063_bib18","first-page":"982","article-title":"Understanding and enhancement of internal clustering validation measures","volume":"43","author":"Liu","year":"2013","journal-title":"IEEE Trans\u00a0Cybernetics"},{"key":"10.1016\/j.acra.2026.06.063_bib19","article-title":"Evaluating the HER-2 status of breast cancer using mammography radiomics features","volume":"121","author":"Zhou","year":"2019","journal-title":"Eur\u00a0J\u00a0Radiol"},{"key":"10.1016\/j.acra.2026.06.063_bib20","first-page":"711","article-title":"Predicting human epidermal growth factor receptor 2 expression in breast cancer based on radiomics of MRI habitat and US","author":"Lin","year":"2025","journal-title":"Breast Cancer: Targets and Therapy"},{"issue":"6","key":"10.1016\/j.acra.2026.06.063_bib21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/cancers13061241","article-title":"Cost-effectiveness of digital breast tomosynthesis vs. abbreviated breast MRI for screening women with intermediate risk of breast cancer\u2014how low-cost must MRI be?","volume":"13","author":"Tollens","year":"2021","journal-title":"Cancers"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226004794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633226004794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:32:33Z","timestamp":1785961953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633226004794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"alternative-id":["S1076633226004794"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2026.06.063","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Habitat-Based Radiomic Quantification of Intratumoral Heterogeneity on Digital Breast Tomosynthesis for Predicting HER2 Status in Invasive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2026.06.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Association of Academic Radiology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}